Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013527 | 1.00 | TSHR (0.48) | TSHRALDH1A1GAABACE1HTR2C | |
| SCHEMBL14244150 | 1.00 | TSHR (0.48) | TSHRALDH1A1GAABACE1HTR2C | |
| SCHEMBL14296735 | 1.00 | TSHR (0.48) | TSHRALDH1A1GAABACE1HTR2C | |
| SCHEMBL15309564 | 1.00 | TSHR (0.48) | TSHRALDH1A1GAABACE1HTR2C | |
| Oxalic Acid SCHEMBL14783050 | 0.98 | TSHR (0.46) | TSHRALDH1A1GAABACE1HTR2C | |
| Oxalic Acid SCHEMBL14783046 | 0.98 | TSHR (0.46) | TSHRALDH1A1GAABACE1HTR2C | |
| Oxalic Acid SCHEMBL28411657 | 0.98 | TSHR (0.46) | TSHRALDH1A1GAABACE1HTR2C | |
| Oxalic Acid SCHEMBL14783047 | 0.98 | TSHR (0.46) | TSHRALDH1A1GAABACE1HTR2C | |
| Oxalic Acid SCHEMBL15309424 | 0.98 | TSHR (0.46) | TSHRALDH1A1GAABACE1HTR2C | |
| Oxalic Acid SCHEMBL28403878 | 0.98 | TSHR (0.46) | TSHRALDH1A1GAABACE1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3269717-B9 | POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104 | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-08-09 | — | — | EP | disclosed |
| EP-3269717-B2 | POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104 | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-06-14 | — | — | EP | disclosed |
| US-9862718-B2 | Sodium salt of (2S, 5R)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1] octane-2-carboxylic acid and its preparation | WOCKHARDT LIMITED (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD (BM) | 2017-07-27 | — | — | US | disclosed |
| US-9695122-B2 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2017-07-04 | — | — | US | disclosed |
| WO-2017045510-A1 | Β-LACTAMASE INHIBITOR AND APPLICATION THEREOF | 山东轩竹医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| US-9580424-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2017-02-28 | — | — | US | disclosed |
| US-20170022160-A1 | PROCESSES FOR PREPARING HETEROCYCLIC COMPOUNDS INCLUDING TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE AND SALTS THEREOF | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2017-01-26 | — | — | US | disclosed |
| EP-2650281-B1 | PROCESS FOR PREPARING CYCLIC AMINE COMPOUNDS | KANEKA CORP (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-9284314-B2 | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2016-03-15 | — | — | US | disclosed |
| US-20140163230-A1 | PROCESSES FOR PREPARING HETEROCYCLIC COMPOUNDS INCLUDING TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE AND SALTS THEREOF | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2014-06-12 | — | — | US | disclosed |
| US-20130303771-A1 | PROCESS FOR PREPARING CYCLIC AMINE COMPOUNDS | KANEKA CORPORATION (JP) | 2013-11-14 | — | — | US | disclosed |
| EP-2650281-A1 | PROCESS FOR PREPARING CYCLIC AMINE COMPOUNDS | KANEKA CORPORATION (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8471025-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-06-25 | — | — | US | disclosed |
| US-20130012712-A1 | METHOD FOR PREPARING DISUBSTITUTED PIPERIDINE AND INTERMEDIATES | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| US-20120323010-A1 | PROCESSES FOR PREPARING HETEROCYCLIC COMPOUNDS INCLUDING TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE AND SALTS THEREOF | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2012-12-20 | — | — | US | disclosed |
| US-8288553-B2 | Method for preparing disubstituted piperidine and intermediates | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-10-16 | — | — | US | disclosed |
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2011-06-23 | — | — | US | disclosed |
| US-20100197928-A1 | METHOD FOR PREPARING DISUBSTITUTED PIPERIDINE AND INTERMEDIATES | NOVEXEL (FR) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | TSHR 772/4885ALDH1A1 4203/4885GAA 2465/4885 |
| US-20130012712-A1 | METHOD FOR PREPARING DISUBSTITUTED PIPERIDINE AND INTERMEDIATES | OGDH, FPGS, PLOD1 | TSHR 4499/4885ALDH1A1 449/4885GAA 258/4885 |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | TSHR 772/4885ALDH1A1 4203/4885GAA 2465/4885 |
| US-20120323010-A1 | PROCESSES FOR PREPARING HETEROCYCLIC COMPOUNDS INCLUDING TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE AND SALTS THEREOF | PYM1, SPIN4, ENO1 | TSHR 1486/4885ALDH1A1 2329/4885GAA 2644/4885 |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | TSHR 772/4885ALDH1A1 4203/4885GAA 2465/4885 |
| US-20130303771-A1 | PROCESS FOR PREPARING CYCLIC AMINE COMPOUNDS | SMS, SRM, PAM | TSHR 909/4885ALDH1A1 2956/4885GAA 3197/4885 |
| US-20140163230-A1 | PROCESSES FOR PREPARING HETEROCYCLIC COMPOUNDS INCLUDING TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE AND SALTS THEREOF | PYM1, SPIN4, ENO1 | TSHR 1486/4885ALDH1A1 2329/4885GAA 2644/4885 |
| US-20100197928-A1 | METHOD FOR PREPARING DISUBSTITUTED PIPERIDINE AND INTERMEDIATES | OGDH, FPGS, PLOD1 | TSHR 4499/4885ALDH1A1 449/4885GAA 258/4885 |
| US-20170022160-A1 | PROCESSES FOR PREPARING HETEROCYCLIC COMPOUNDS INCLUDING TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE AND SALTS THEREOF | PYM1, SPIN4, ENO1 | TSHR 1486/4885ALDH1A1 2329/4885GAA 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.